Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
Yoshinori Munemoto(Fukui-ken Saiseikai Hospital), Hideyuki Mishima(Aichi Medical University Hospital), Mitsuro Kanda(Nagoya University), Junichi Hasegawa(Osaka Rosai Hospital), Taishi Hata(The University of Osaka), Michitaka Nagase(Gifu University), Masaki Matsuoka(Matsushiro Seismological Observatory), Toshio Otsuji(Nara City Hospital), Akinori Takagane(Iwate Medical University), Michiya Kobayashi(Kochi Medical School Hospital), Keiichiro Ishibashi(Saitama Medical University), Mutsumi Fukunaga(Sakai Municipal Hospital), Junichi Sakamoto(Tokai Central Hospital), Yasuhiro Miyake(High Energy Accelerator Research Organization), Koji Oba(The University of Tokyo)
Cited by 18
Related Papers
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
A new approach for measuring the muon anomalous magnetic moment and electric dipole moment
|Progress of Theoretical and Experimental Physics|2019|239
Sensitivity and Specificity of Des-Gamma-Carboxy Prothrombin for Diagnosis of Patients with Hepatocellular Carcinomas Varies According to Tumor Size
|The American Journal of Gastroenterology|2006|165